Description
The Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay is a two-step enzyme-linked immunosorbent assay. Wells of a 96-well microtiter plate are coated with recombinant SARS-CoV-2 Spike protein S1 (RBD). After addition of human serum or plasma samples anti-S1 IgG antibodies from the sample bind to the immobilized antigen during a two hours incubation followed by several washing steps in order to remove unbound components. The bound anti-SARS-CoV-2 IgG antibodies are detected by incubation with HRP conjugated anti-human IgG for 30 minutes. After removal of nonspecific bindings a HRP substrate solution containing 3,3’,5,5’-Tetramethylbenzidine (TMB) is added resulting in the formation of a blue color. The reaction is terminated by the addition of 0.2 M H2SO4 changing the blue color into yellow signals which are measured by an absorbance microtiter plate reader at 450 nm. The extinction increases with the amount of the captured IgG antibodies directed against SARS-CoV-2-S1 (RBD) from the sample